Phase 1 Clinical Trials Program

Phase 1 Clinical Trials Program
at Karmanos Cancer Institute

The Barbara Ann Karmanos Cancer Institute has one of the largest and best clinical trial programs in the United States, giving patients better access to new cancer treatments. Our patients have access to more than 250 promising new cancer treatments often available only at Karmanos Cancer Institute. 

Karmanos has patients actively participating in more than 800 clinical trials, which are developed and sponsored by our own physicians and researchers, major pharmaceutical companies or national cooperative group programs funded by the National Cancer Institute (NCI).

As part of our robust clinical trials program, Karmanos runs a Phase I Clinical Trials program. We are a participating site in the Early Therapeutics Clinical Trials Network (ET-CTN) of the NCI —with Karmanos being the only site in Michigan. The Phase I Clinical Trials program assists with early drug development.

Program Mission

To offer hope and longer life to patients with all types of cancer by making available the newest types of therapy, by creating new knowledge about how these therapies fight cancer and by providing national leadership in testing these new therapies.

What is a Phase I Clinical Trial?

A typical Phase I clinical trial evaluates how a new drug should be given, either orally or injected into the blood, how often and what dosage is safe. A Phase I trial is often the first time a drug has been given to human, or the first time a new drug has been given to a human in combination with another standard cancer treatment. Because we are working with new drugs, most Phase I trials only enroll a small number of patients.

Phase I clinical trials provide the initial pieces of critical information about the effect of a new drug on humans which is necessary for future clinical development. Once the initial Phase I trial is complete, drug development may progress into larger clinical studies that continue to test the safety of the new drug and how well it works in treating a particular type of cancer.

The Phase I Team meets with and treats patients at the state-of-the-art Eisenberg Center for Translational Therapeutics, located at the Karmanos Cancer Center’s midtown Detroit campus.

Phase I Clinical Trials Program Team

  • Ulka Vaishampayan M.D.
    Team Leader, Phase I Clinical Trials Program
  • Hirva Mamdani, M.D.
    Medical Oncology
  • Anthony Shields M.D., Ph.D.
    Medical Oncology
  • Lisa Lange, ANP-BC, AOCN
    Director, Translational Research Program

Appointment Information 

To schedule an appointment with the Karmanos Phase I Clinical-Pharmacology Team, call (313) 576-8765 or request an appointment online.

Make a Donation

For patients with advanced cancer who have exhausted conventional treatments, Phase I clinical trials offer the last, best hope: tomorrow's drugs today.Your generous contribution will go directly to the Phase I Team to ensure patients continue to have access to the novel therapies that may increase their quality of life and give them more precious time with their loved ones. Donate Now